A. V. Pavlov

A. V. Pavlov

Auto-generated profile, based on publicly available information

A. V. Pavlov

Bashkir State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
NZNaufal Zagidullin
Naufal Zagidullin
DGDiana Gareeva
Diana Gareeva
VIV. Sh. Ishmetov
V. Sh. Ishmetov
APA. V. Pavlov
A. V. Pavlov
MPM. R. Plotnikova
M. R. Plotnikova
VPV. N. Pavlov
V. N. Pavlov
Ренин-ангиотензиновая система при новой коронавирусной инфекции COVID-2019

14 December 2020 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
DGDiana Gareeva
Diana Gareeva
TMT. I. Musin
T. I. Musin
VPValentin Nikolaevich Pavlov
Valentin Nikolaevich Pavlov
PDP. A. Davtyan
P. A. Davtyan
VIV. Sh. Ishmetov
V. Sh. Ishmetov
ККК. Карвальо
К. Карвальо
The COVID-19 pandemic has had a huge impact on the health of millions of people around the world on an unprecedented scale. Unfortunately, the process of creating effective antiviral drugs and vaccines is being delayed. Therefore, drugs that are already available and may have an effect on COVID-19 are being investigated. Due to the fact that viral infection often affects the cardiovascular system, causing myocardial infarction, viral myocarditis, tachyarrhythmias and stress cardiomyopathies, a theory was put forward that HMG-CoA reductase (3-hydroxy-3methyl-glutaryl-CoA reductase) inhibitors (statins) can reduce the risk of cardiovascular complications in these patients. In recent years, this class of drugs has been proposed, including for viral infections, such as the influenza virus or MERS-CoV. The review discusses both the latest clinical data on the efficacy of statins in COVID-19 and the pleotropic mechanisms of statins that can limit the pathogenic effect of viruses. In particular, statins can act on lipid cell rafts (subdomains of the plasma membrane), decreasing their lipid concentration; limiting the interaction of the virus with the receptors of angiotensin-converting enzyme-2 and CD-147. Statins have an antiinflammatory effect (blocking the molecular mechanisms of inflammation, including NF-κB and NLRP3), limit the development of a “cytokine storm” in severe patients with COVID-19; can inhibit SARS-CoV-2 basic protease; influence coagulation, limit sympathetic activity and have other effects. In two large cohort observational studies (n = 96032 and n = 13981), hospitalized patients with COVID-19 who were taking statins showed a decrease in hospital mortality and mortality 28 days after the admission to the hospital. Thus, statins can play a role in the treatment of COVID-19.